Blaker

This research aims to compare the impact of nutritional counseling versus no treatment on patients diagnosed with schizophrenia, psychosis, or bipolar affective disorder. These mental health conditions are linked to a shorter life expectancy mainly due to a higher risk of cardiovascular diseases, often caused by lifestyle factors like smoking, inactivity, and poor diet. The study seeks to understand if nutritional counseling can help prevent cardiovascular problems in these patients. Participants will be randomly divided into two groups one group will receive individualized nutritional counseling based on baseline assessments, while the other group will not receive this intervention during the study period. The counseling sessions last a total of 60 minutes split into two 30-minute parts with a break, following national dietary guidelines aimed at preventing cardiovascular disease. After six weeks, the control group will be offered the same counseling. During the study, participants will meet a nutritionist for initial measurements including nutritional status, biochemical markers, and body measurements. These assessments will be repeated after six weeks to identify any changes between the groups. Researchers will monitor cholesterol levels, blood sugar, weight, waist circumference, blood pressure, and dietary habits to evaluate the effects of the counseling. The total study duration for each participant is six weeks, with careful monitoring of health markers related to cardiovascular risk.

Researchers are comparing two main therapies for post-traumatic stress disorder PTSD called eye movement desensitization and reprocessing EMDR and cognitive therapy for PTSD CT-PTSD. This large, long-term study aims to understand how well these treatments work in Norwegian specialist health care. The study will look at how these therapies affect PTSD symptoms, other related disorders, complex PTSD symptoms, and how patients function after treatment. It will also explore the role of the therapeutic relationship and long-term effects over time. Participants will be randomly assigned to receive either EMDR or CT-PTSD, each following a set treatment plan of up to 24 weekly therapy sessions. If no clear improvement is seen after 10 sessions, treatment may be stopped. EMDR focuses on processing trauma memories while using bilateral stimulation to reduce distress, while CT-PTSD uses cognitive techniques like restructuring thoughts and controlled exposure to trauma memories. Both therapies are provided in line with patient treatment goals. During the study, patients will complete digital questionnaires before treatment and after each therapy session to report symptoms of PTSD, depression, anxiety, psychosis, substance use, and functional outcomes. Researchers will monitor changes in PTSD symptoms from the start to the end of treatment at 24 weeks, with follow-ups at 3, 6, and 12 months. They will also assess effects on comorbid illnesses, functional outcomes, and the quality of the therapeutic alliance. The study lasts over a year, including treatment and follow-up assessments.

Researchers are investigating the safety and effectiveness of combining anti-PD-1PD-L1 treatment with UV1 vaccination compared to anti-PD-1PD-L1 treatment alone in patients with advanced or metastatic non-small cell lung cancer NSCLC who cannot have surgery. The phase 2 trial aims to improve progression-free survival in patients with stage IIIBIIIC or IV NSCLC by using these treatments. The study evaluates whether adding UV1 vaccination can provide additional benefit alongside standard anti-PD-1PD-L1 therapies. Participants are randomly assigned to receive either anti-PD-1PD-L1 treatment alone or combined with UV1 vaccination and sagramostim. The anti-PD-1PD-L1 treatment continues until disease progression or unacceptable side effects, up to two years. Patients in the UV1 vaccination group receive eight total injections the first dose on the same day as starting anti-PD-1PD-L1 treatment, three more within the next ten days, and one vaccination during treatment cycles two through five. During the study, participants undergo regular evaluations including imaging scans to measure tumor response according to RECIST 1.1 criteria. Researchers monitor progression-free survival over up to two years. Safety is continuously assessed and adverse events are tracked during treatment and for four months afterward. The study involves blood tests, tumor tissue analysis, and performance status assessments to evaluate organ function and overall health throughout participation.